NCT06679829View on ClinicalTrials.gov

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Siltuximab

11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).

DRUG

Melphalan

"Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2"

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

RECORDATI GROUP

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER